Nektar Therapeutics traded at $3.97 this Wednesday June 29th, decreasing $0.05 or 1.24 percent since the previous trading session. Looking back, over the last four weeks, Nektar Therapeutics lost 14.08 percent. Over the last 12 months, its price fell by 76.86 percent. Looking ahead, we forecast Nektar Therapeutics to be priced at 3.92 by the end of this quarter and at 3.61 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
3.97
Daily Change
-1.24%
Yearly
-76.86%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,799.00 -3.00 -0.08% 2.15%
Eisai 5,800.00 88.00 1.54% -46.91%
Agios Pharmaceuticals 22.59 -0.03 -0.11% -59.02%
ALKERMES 30.06 -0.33 -1.09% 22.59%
Amgen 245.69 2.18 0.90% 0.80%
Astrazeneca 67.13 1.20 1.82% 12.07%
Baxter International 65.08 -0.17 -0.26% -19.16%
BioCryst Pharmaceuticals 10.61 0.15 1.39% -31.54%
Biogen 204.27 1.76 0.87% -41.01%
Bluebird Bio 4.27 0.23 5.69% -85.80%
Bristol-Myers Squibb 78.43 -0.27 -0.34% 17.38%
Cara Therapeutics 9.25 -0.01 -0.11% -35.18%
Dr.Reddys Laboratories 4,365.00 -9.60 -0.22% -19.51%
Esperion Therapeutics 6.38 0.11 1.75% -69.83%
Exelixis 20.78 -0.17 -0.79% 14.02%
Gilead Sciences 62.57 0.36 0.58% -9.13%
GlaxoSmithKline 1,793.00 27.00 1.53% 26.32%
Halozyme Therapeutics 45.40 -0.38 -0.83% -0.02%
Immunogen 4.31 0.02 0.47% -34.60%
Incyte Corp 75.58 -0.05 -0.07% -10.16%
Ionis Pharmaceuticals 38.11 0.14 0.37% -4.46%
Ironwood Pharmaceuticals 11.54 0.01 0.04% -10.37%
Karyopharm Therapeutics 4.44 -0.14 -3.06% -56.98%
Eli Lilly 322.74 5.12 1.61% 40.62%
MacroGenics 2.95 -0.06 -1.99% -89.02%
Merck & Co 92.25 0.36 0.39% 18.62%
Mirati Therapeutics 68.72 0.22 0.32% -57.46%
Neurocrine Biosciences 97.90 0.97 1.00% 0.60%
Nektar Therapeutics 3.97 -0.05 -1.24% -76.86%
Novartis 81.19 0.05 0.06% -3.71%
Pfizer 50.95 0.29 0.57% 30.11%
Roche Holding 319.65 2.10 0.66% -8.29%
Seattle Genetics 178.67 0.20 0.11% 13.17%
Sarepta Therapeutics 76.19 1.52 2.03% -2.00%
Teva Pharmaceutical Industries Ltd 2,753.00 -78.00 -2.76% -15.16%
Xencor 26.78 -0.28 -1.03% -22.35%

Indexes Price Day Year
USND 11139 -43.03 -0.38% -23.20%
US2000 1711 -28.32 -1.63% -25.97%
US400 2281 -28.58 -1.24% -15.41%

Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.